Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Romosozumab in postmenopausal South Korean women with osteoporosis
NCT02791516Phase 3Completed
- Sponsor
- Amgen
- Start
- Jan 2017
- Primary completion
- Feb 2018
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in postmenopausal osteoporosis comparing Romosozumab with Placebo (2 arms). Primary endpoint: Percent Change From Baseline to Month 6 in Bone Mineral Density at the Lumbar Spine. Started Jan 2017; status: completed.
02
Drugs
romosozumab
03
Conditions
postmenopausal osteoporosis
Beyond the preview
Go deeper on NCT02791516.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02791516.